background: Pregnant women with breast cancer present with a more advanced disease compared with non-pregnant women.
Introduction
Maternal malignancy during pregnancy is estimated to occur in 1 out of 1000 pregnancies (Al-Adnani et al., 2007) . Since maternal age at conception continues to increase, the incidence of such cases is expected to rise (Pereg et al., 2008) . Controversy exists regarding the effect of pregnancy on cancer prognosis, especially breast cancer and melanoma (Al-Adnani et al., 2007; Driscoll et al., 2009) . Breast cancer is the most common malignancy affecting women worldwide (KeinanBoker et al., 2008) . Approximately 10% of breast cancer patients under the age of 40 are diagnosed during pregnancy (Beadle et al., 2009) . Numerous studies have found that pregnant women with breast cancer have larger tumors and are more likely to have metastases and positive nodes compared with non-pregnant women (Woo et al., 2003; Pereg et al., 2008; Rodriguez et al., 2008) . The reason for this is not yet clear, although, a delay in diagnosis due to pregnancy has been suggested as a possible cause. A theory that gestational hormones and pregnancy-related growth factors may induce a more aggressive behavior in malignant cells (Schedin et al., 2006; Rodriguez et al., 2008 ) is yet to be proven. Biologically, the level of estrogen receptor alpha (ERa) in the breast cancer cells of pregnant patients is lower than that in non-pregnant women (Shousha et al., 2000) . Generally, ERa negative tumors are often less differentiated, and patients tend to have a decreased overall survival rate (Putti et al., 2005) .
Despite the advanced breast cancer found in pregnancy, metastasis to the products of conception is rare (Al-Adnani et al., 2007) . Approximately 80 cases of placental and/or fetal metastatic involvement originating from maternal cancer have been reported since 1866 (Al-Adnani et al., 2007) .
Malignant melanoma is the most common malignancy involving the placenta, accounting for 30% of placental metastasis, followed by lung (16%), hematological malignancies (15%), breast (13%) and other cancers (26%) (Al-Adnani et al., 2007) . The uteroplacental blood flow represents 10% of maternal cardiac output and thus, hematogenous spread of maternal tumor-emboli to the placenta is not unexpected (Tolar et al., 2003) . Therefore, the limited number of placental metastasis from maternal tumors suggests that the placenta may be a non-supporting microenvironment for cancer cells. Investigation of the causes of impaired cancer cell growth near the placenta may suggest biological pathways for this phenomenon and future therapeutic targets.
Metastases cause 90% of all cancer deaths (Yilmaz et al., 2007) . Secondary tumors are formed by cancer cells that have left the primary tumor mass and traveled to new sites, mainly through blood and lymphatic vessels. Metastasis occurs when cancer cells detach from neighboring tumor cells and extracellular matrix (ECM), and gain migratory and invasive capabilities; processes that demand changes in adhesion molecules and tight junctions (Kopfstein et al., 2006) . Cell migration can be broadly divided into collective or single cell. Collective migration of cells, observed in several carcinomas, including mammary, consists of multiple cells that are mobile, yet simultaneously connected by cell-cell junctions (Friedl et al., 2009) . Migration is regulated by signaling cascades such as Rho small GTPases and by activating proteases, especially matrix metalloproteinase 2 (MMP2) (Wolf et al., 2007) . Following detachment and migration, cancer cells extravasate into a new environment where they seed and grow as secondary tumors. Neighboring cells in the metastatic niche influence cancer cell behavior by secreting various ECM proteins, chemokines, cytokines, growth factors, proteases and protease inhibitors (Schedin et al., 2004) , which may restrain or encourage cancer cell growth in the new metastatic sites (Paget et al., 1989; Hu et al., 2008) . Thus, the ability of cancer cells to form new colonies in the placental area may be related to the placenta's ability to support cancer growth.
Placental cells (trophoblasts) are capable of invasive processes and are able to protect themselves from the maternal immune system. Malignant tumor cells have similar characteristics (Soundararajan et al., 2004; Cohen et al., 2007) and tumoric and trophoblastic invasions share the same biochemical mediators (Bilban et al., 2009) . However, trophoblastic invasion during implantation is stringently controlled (Cohen et al., 2007) . We hypothesized that the mechanisms that restrain trophoblast cell invasion into maternal tissue may also be responsible for the inhibition of metastatic growth in the placental area.
Human trophoblast stem cells differentiate along two pathways: syncytiotrophoblast and extravillous trophoblast (EVT) cells. Cytotrophoblast cells within the placental villi differentiate into syncytiotrophoblasts and mediate nutrient and gas exchange between mother and fetus. A second pathway involves the differentiation of cytotrophoblast cells in the anchoring placental villi into EVT cells, which invade through the maternal tissue and associate with the decidual blood vessels (Yamamoto et al., 2009) . First trimester human placenta secretes several factors, including hormones (such as progesterone and estrogen), growth factors (such as GM-CSF) and cytokines (such as IL6, LIF) (Bowen et al., 2002; Cohen et al., 2007; Fitzgerald et al., 2008) . Placental cells may also synthesize a number of apoptosis triggering molecules, such as TNF-a (Bowen et al., 2002) and induce death of the neighboring cells (Bowen et al., 2002) . These factors may also affect the migration, invasion, proliferation and death of breast cancer cells.
In this study, we wished to evaluate the effects of first trimester human placental explants on breast cancer cells. We used the placental explant model that was developed by Miller (Genbacev et al., 1992) , where trophoblast cells differentiate into EVT cells and are released from the anchoring villi to the matrigel substrate. We co-cultured breast cancer cells (MCF-7/T47D cell lines) with the placental explants during EVT cell differentiation and invasion. Our study demonstrates that MCF-7/T47D cells are eliminated from the area surrounding the EVT cells, especially by migrating/detaching from this area.
Materials and Methods

Cell lines
MCF-7/T47D breast cancer cells (kindly provided by Prof. Z. Malik, Bar Ilan University and by Dr Ilan Tzarfati, Tel Aviv University) were maintained in DMEM medium supplemented with L-glutamine (2 mM), fetal calf serum (FCS:10%) and antibiotics. MCF-7 eGFP/T47D-eGFP tagged cells were cultured in the presence of G418 antibiotics (Biological Industries, Beit Haemek, Israel).
Antibodies
A list of the antibodies used is represented in Supplementary, Table S1 .
Transient and stable transfection of plasmid DNAs
The eGFP expression vector eGFP-C1 (C1 vector) was purchased from Clontech (Mountain View, CA, USA). The plasmid was introduced into T47D/MCF-7 cells by FuGENE 6 transfection reagent (Roche), according to the manufacturer's instructions. Briefly, 3 × 10 5 T47D/MCF-7 cells were grown in 2 ml of growth medium overnight. Three microliters of FuGENE 6 reagent were added to 97 ml of OPTI-MEM I (serum-free medium), mixed, and incubated for 5 min at room temperature. One microgram of plasmid DNA was added to the mix and incubated for 30 min at room temperature. Then, the entire volume of the tube was added to the well that contained breast cancer cells. Forty-eight hours following transfection, cells were grown in the presence of selective factor G418 antibiotic (concentration; 300 mg/ml). Transfection efficiency was estimated according to the proportion of eGFP positive cells identified by FL1 (FITC) fluorescence with Coulter Flow Cytometer (FACS; EPICS-XL, Beckman Coulter, Fullerton, CA, USA). Following transfection, T47D/MCF-7 cells were exposed to 300 mg/ml G418 (Clontech) for 2 weeks. The cells were sorted (cell sorter) and only eGFP expressing cells continued to grow in medium containing G418.
Placental culture and co-culture experiments
The local ethics committee approved the use of placental tissues. Placentae, 6 -9 weeks gestational age, were retrieved from terminated normal pregnancies. Placental villi were dissected from the fetal membranes. Explants of 10 mg wet weight were transferred into culture dish inserts ) were added to the placenta. As a control, breast cancer cells, CAG cells and placentae were cultured alone on matrigel. Media from the well (bottom) and the inserts (top) were replaced 24 and 72 h following placental culture and top media were collected and stored at -808C for further MMP analysis. After 96 h of placental culture, inserts containing placental explants, breast cancer cells, or both were fixed, paraffin embedded and sectioned for further immunohistochemical analysis. Breast cancer cells tagged with eGFP were either treated the same as the non-tagged cells or retrieved from the matrigel by trypsin and sorted by their eGFP expression for future cell cycle and protein analyses.
Cell sorting
Breast cancer and placental derived cells were harvested 96 h post-seeding and passed several times through a syringe for clump dispersion. Next, cells (5 × 10 6 per ml in PBS supplemented with 10% FCS) were isolated and collected using a BD FACSAria cell sorter (BD biosciences). Matching cells treated with respective transfection reagent only, were considered negative for eGFP and used for calibration of eGFP cell threshold. 
Breast cancer cell adhesion to plastic platform
Immunohistochemistry
Immunohistochemistry procedures were employed for: MCF-7/T47D cells and placental proliferation (using anti-Ki67), MCF-7/T47D cells and placental apoptosis (using anti-fragmented Parp/anti-fragmented caspase 3), MCF-7/T47D cells ERa analysis and for CD138 a marker for Myeloma cells (in CAG Myeloma co-culture).
Since MCF-7 cells do not contain caspase 3 and Parp is only partially cleaved in T47D cells, we had to evaluate fragmented Parp to identify MCF7 apoptotic cells and fragmented caspase 3 for analysis of T47D and apoptotic trophoblast cells.
In order to differentiate between EVTs and breast cancer cells, doublestaining procedures, which included eGFP staining of the breast cancer cells (positive to eGFP and negative to HLA-G) or HLA-G staining of the EVT cells (positive to HLA-G and negative to eGFP) were used in the co-culture experiments. Both systems provided a control for each other: whereas eGFP identifies only MCF-7/T47D-eGFP cells, the other staining combination avoids any suspected cross-reaction that could occur because of the addition of the eGFP tag to the breast cancer cells.
A total of six co-culture experiments were done, three of each method. Both sets of experiments gave the same results and thus they were combined (proliferation/apoptosis analysis of MCF-7 cells, apoptosis analysis of T47D cells, proliferation analysis of T47D cells was done only with nontagged T47D cells). For both systems, paraffin-embedded sections were deparaffinized in xylene and alcohol, rinsed in phosphate buffered saline (PBS), immersed in EDTA buffer (pH 8) and heated in a 700 W microwave oven for 15 min. Endogenous peroxide activity was quenched in 3% H 2 O 2 (in PBS). Samples were covered with normal blocker serum and incubated with the appropriate primary antibody (Ki67, caspase 3, fragmented Parp, or ERa) over night. Following washing, the slides were incubated with horseradish peroxidase labeled polymer conjugated to the second antibody, washed and developed with AEC (ECL kit, Santa Cruz, CA, USA). After rinsing, denaturing solution for double stain procedures was added and washed (Biocare Medical, Concord, CA, USA). Then, the slides were incubated with the second primary antibody (antieGFP in the co-culture system of eGFP tagged cells or anti-HLA-G in the co-culture system of non-tagged cells). Following rinsing with PBS, the slides were incubated with biotinylated antibody covered with streptavidin alkaline phosphatase and developed with BCIP/NBT-chromogen (Chemicon International, Temecula, CA, USA). The same procedures were used to evaluate trophoblast cell proliferation (Ki67 staining) and apoptosis (caspase 3 and fragmented Parp staining) following their co-culture with the breast cancer cells and in controls. Isotype-matched control antibodies were used and excluded non-specific staining of the tested antibodies.
Cell counting
Cell counting procedures were employed for evaluation of immunohistochemistry procedures and breast cancer cell distribution around the placental explants. Immunohistochemistry: microscopic evaluation (×400) allowed enumeration of stained from non-stained cells. We evaluated breast cancer staining (Ki67/caspase 3/Parp/ER/) in co-cultures (placental explants + breast cancer cells) versus breast cancer cells that were cultured alone. We also evaluated the number of Ki67 and caspase 3 stained trophoblast cells versus non-stained cells in placental explants that were co-cultured with breast cancer cells and on placentae that were cultured alone as a control. Three to six different placentae were used for each analysis. Every test for each treatment and experiment was performed on three to four explants. Thus, at least 18 slices were counted for every treatment (3 placentae × 3 explants × duplicate for each explant). In order to evaluate the number of MCF-7 cells located around different areas of placentae (with/without EVT cells) we combined cell number data from all double-staining procedures (Ki67/HLA-G, Parp/HLA-G, ER/HLA-G, altogether: 18 slides × 3) and counted all the cells that were located around the explants; separating between areas that contained EVT cells (positive for HLA-G) and areas that did not contain EVT cells (negative for HLA-G).
Breast cancer cell distribution around the placental explants T47D/MCF-7 cell distribution was evaluated by visual observation and cell counting under a contrast phase microscope (Nikon 'Labphot' light microscope). After 96 h in culture, the wells were photographed. Quantitative analysis was achieved by dividing the area surrounding the placental explant into 1 mm squares and counting the number of cancer cells in
The effect of human placenta on breast cancer cells each and in squares positioned in photographs of control wells (breast cancer cells cultured alone). EVT differentiation and migration can be morphologically identified by microscopic observation as fingerlike outgrowth projections that surround the placental explants, which are later accompanied by individual EVT cells that bud from the villous tips into the matrigel (Methods in Toxology, 38: 246, 1993) . Thus, we could discriminate between placental areas from which EVT cells differentiated and migrated to the matrigel and other placental areas that did not contain EVT cells. Furthermore, fluorescence microscopy demonstrated that these extravillous cells were indeed negative for eGFP and were not of breast origin.
Cell cycle analysis
Cells were retrieved from the matrigel by trypsinization and suspended in PBS (Biological Industries, Beit Haemek, Israel) containing 0.5% formaldehyde (Gadot, Biochemical Industries, Haifa Bay, Israel) and 0.1% sodium azide (Sigma Aldrich, St Louis, MO, USA) for 1 h at 48C. Fixation was followed by washing in ice-cold PBS and then the cells were re-suspended in 70% ethanol/PBS overnight at 2208C. The following day, cells were exposed to 40 mg/ml propidium iodide (PI) (Sigma Aldrich) and 100 mg/ml Ribonuclease A in PBS for 30 min at room temperature in the dark, and later read by flow cytometry (EPICS-XL, Beckman Coulter). Results were analyzed using either WinMDI 2.8 or ModFit LT 3.0 programs (Verity Software House, Inc., Topsham, ME, USA). Cell cycle analysis was done only to the eGFP tagged cells (breast cancer cells).
Cell death analysis
Annexin V-PE (BioVision, Mountain View) supplemented with 0.1 mg 7AAD (eBioscience, San Diego, CA, USA) was use to detect exposed phosphatidylserine according to the manufacturer's instructions and assayed for fluorescence by FACS (EPICS-XL, Beckman Coulter, UK). Cells that were positive for Annexin V and negative for 7AAD were considered apoptotic, whereas cells positive for both were defined as late apoptotic or necrotic cells.
Western blotting
MCF7 eGFP/T47D-eGFP cells were separated from the placental explants by cell sorter and lysed in buffer that contained 50 mM Hepes, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 50 mM NaF, 10 mM NaPPi, 2 mM NaVO3, 10 mM EDTA, 2 mM EGTA, 1 mM PMSF, 10 mg/ml Leupeptin for 10 min on ice. Then 20-30 mg protein lysate mixed 1:5 with loading buffer was denatured for 10 min at 658C and separated on SDS -PAGE followed by semi-dry transfer to PVDF membrane. After blocking the nonspecific binding sites with 5% milk powder, the membranes were incubated overnight at 48C, with the anti-ERa antibody. Equal protein loading was confirmed with the anti-tubulin antibody. Primary antibody was rinsed with Tris-buffered saline (TBS) with and without 0.1% Tween. Bound antibodies were visualized using horseradish peroxidase conjugated secondary antibody (Vector Laboratories, Marion, IA, USA) and enhanced chemiluminescence (ECL) detection (ECL kit, Amersham Pharmacia, Piscataway, NJ, USA). Optical densities of immunoreactive protein bands were measured using Gel Analyzer software (Media Cybernetics, Bethesda, MD, USA) (arbitrary units) and normalized to tubulin values.
Gelatin zymography
Collected supernatants were assayed for MMP2/9 gelatinase activity. Aliquots (20 ml) of the media were electrophoresed at non-reducing conditions in 10% polyacrylamide gel containing 1 mg/ml gelatin type A (Sigma). Gels were washed twice in 2.5% Triton X-100 for gelatinase renaturation and incubated overnight in 50 mM Tris -HCl (pH 7.5) and 5 mM CaCl 2 . Coomassie blue staining followed by destaining allowed visualization of clear lysis zones against a blue background. Band intensity was calculated for each example. Standardized activated and proactivated MMP2/9 (Chemicon, Temecula, CA, USA) was electrophoresed near the experimental samples to validate the identity of the MMP. Gels were analyzed employing Gel Doc 2000 (Bio-Rad Laboratories, Hercules, CA, USA).
Statistical analysis
Paired Student's t-tests were used to analyze differences between cohorts. A P-value of ≤0.05 was considered significant. All experiments were repeated separately three to six times.
Results
The area around the placental explant had fewer breast cancer cells
Following 96 h of MCF-7/T47D cell culture on matrigel, most of the cells were arranged in aggregates, the remainder as single cells. Counting cells in photographs of placenta-breast cancer cell co-culture and sorter data demonstrated reduced breast cancer cell numbers near the area of the placental explant (.40% reduction, P , 0.05, Fig. 1a-g ). Additional studies with MCF-7 cells demonstrated their absence, especially from regions located near EVT-releasing villi (Fig. 1h) . Significantly fewer MCF-7 cells were found in the area surrounding the EVT cells compared with cultures with no placental explant (80 and 46% decrease in aggregate and single cells, respectively, compared with control, P , 0.05). Furthermore, we counted the number of cells located around placental explants in slides stained for HLA-G (EVT marker) of placental-MCF-7 cell co-culture and controls. Results showed significantly reduced MCF-7 cells number near placental areas with EVT cells compared with placental area that did not contain EVT cells and compared with control slides (42 + 5.7, 107+8.6, 219 + 37.6 cells/slide, respectively, P , 0.05).
Placental explant reduced the number of breast cancer proliferating cells
The decrease in the number of breast cancer cells in the area surrounding the placental explant could be a result of reduced proliferation, increased apoptosis and/or cell detachment/migration from the placental area. To evaluate the effect of placental explants on the breast cancer cell proliferation rate, inserts with the co-cultured cells were fixed and stained. Proliferation was determined based on Ki67 staining (Fig. 2a-c) . Decreased Ki67 staining was detected in MCF-7 cells located near the placenta compared with cells cultured alone (11% decrease, P , 0.05, Fig. 2d) . A similar, yet not statistically significant decrease, was observed in T47D cells (10% decrease, P ¼ 0.14, Fig. 2d ). Additional studies with MCF-7 cells demonstrated that the reduced Ki67 staining was observed in aggregates located near EVT releasing villi (Fig. 2e) , whereas MCF-7 single cells that were located near the placental area in which EVT cells were not observed had increased proliferation (Fig. 2e, ' MCF-7 + Placenta No EVT'). Furthermore, cell cycle analysis (FACS) of MCF-7 eGFP cells cultured with/without placental explants showed the placenta to elevate the sub-G1 fraction in comparison with control (Table I, Fig. 2f) , indicating an elevated cell death rate. However, analysis of the cell cycle data without the sub-G1 phase (i.e. 100% cells ¼ all phases except sub-G1) demonstrated no differences in the percentage of G1 and S phases in MCF-7 cells cultured with placental explants compared with controls, indicating that MCF-7 cell proliferation was not arrested by the placenta. Thus, the decreased Ki67 expression could be a result of the elevated sub-G1 fraction. (MCF-7) ; n ¼ 3 (T47D)]. Cells were counted in 1 mm 2 squares that were positioned around the placental explants or in the middle of the control wells (MCF-7/T47D cells cultured alone). Four to five placental explants and controls wells were tested for each experiment, which included counting cells in 26 + 1/22 + 3 squares (MCF-7) and 20.3 + 4/23 + 10 squares (T47D) in each experiment and control, respectively. In (g), we did not differentiate between villi that release EVT cells and other villi, whereas in (h), we separated between these two placental areas (only done with MCF-7 cells). Statistically significant differences are indicated (*, P , 0.05). Figures were taken with ×4 magnification. BCCL, breast cancer cells; EVT, extravillous trophoblast cells.
The effect of human placenta on breast cancer cells
The placental explant increased breast cancer cell apoptosis
Since we observed decreased numbers of MCF-7/T47D cells and an elevated sub-G1 phase in MCF-7 cells that were located near placental explants, we analyzed their apoptotic rates. Apoptosis was determined with Parp p85 fragment staining in MCF-7 cells and with caspase 3 staining in T47D cells (Fig. 3a-c) . A significant increase in apoptosis was found in MCF-7 cells located near placental explants compared with MCF-7 cells cultured alone (Fig. 3d, 17versus 3% , respectively, P , 0.05). These results match those observed in the cell cycle analysis (17versus 4.7%, sub-G1 phase in MCF-7 cells cultured with and without placental explants, respectively). A small but significant increase in apoptosis was also observed in T47D cells located near placental explants compared with T47D cells cultured alone (3.2versus 1.5%, respectively, P , 0.05; Fig. 3d ). Additional studies with MCF-7 cells demonstrated that increased fragmented Parp staining was observed especially in single cells located near placental EVT releasing villi (Fig. 3e) .
The effect of co-culture on breast cancer cell distribution, morphology and MMP secretion
The reduced proliferation and elevated cell death of MCF-7/T47D cells co-cultured with placental explants afforded partial and limited explanation for the cancer cells' absence from the EVT area. Therefore, we assumed that other mechanisms such as cell migration/ detachment were responsible for these phenomena. In an attempt to understand the chronology of events in the elimination of breast cancer cells, we examined MCF-7/T47D cells cultured with and without placental explants at earlier time points (0, 2, 4, 6, 24 and Results are mean + SE (n ¼ 6, MCF-7/T47D). Three to four wells of placental explants co-cultured with MCF-7/T47D cells (BCCL + placenta) and of MCF-7/T47D cells cultured alone (BCCL) were analyzed in each experiment. All cells in two slides were counted for each well of the placental explant co-cultures and controls. The average count for each experiment was 882 + 234 and 1434 + 174 cells for placenta + MCF7 and control treatments, respectively, and 870 + 108 and 906 + 132 for placenta + T47D and control treatments, respectively (cell number X2 slides X3 explants). Statistically significant differences are indicated (*P , 0.05). BCCL, breast cancer cells.
The effect of human placenta on breast cancer cells 72 h). Immediately after the addition of MCF-7/T47D cells to the placental explant cultures, the breast cancer cells dispersed around the placental explants (Fig. 4a, 1 h) . Two hours post-seeding, the T47D cells close to the placenta changed their morphology to a fibroblastlike shape, whereas the MCF-7 cells maintained their primary morphology. Five to 6 h after seeding, MCF-7 and T47D cells cultured both with/without placental explants started to form aggregates on the matrigel (Fig. 4a, 5-6 h ). Ten to 24 h after seeding, large clusters of MCF-7 cells were formed in both settings; however, the clusters located near the placental areas created strands and many were positioned vertically to the explants (Fig. 4a, 10-17 h) . In contrast, T47D cells were arranged in small clumps and T47D cells located close to EVT cells had a fibroblast-like shape (Fig. 4c, 24 h ). Again, fewer T47D/MCF-7 cells were observed, especially near EVT releasing placental villi compared with controls. By 72 h after culturing, most of the MCF-7/T47D cells located near the placental explants had disappeared (Fig. 4a, 24 h and Fig. 4c, 72 h ). However, MCF-7/T47D cells that were cultured alone on the matrigel were still growing in aggregates (Fig. 4b, d ) around the wells. The quick cluster formation of MCF-7 cells, the morphologic change of T47D cells to fibroblastlike cells following their co-culturing with the placenta explants, and the eventual rapid relocation of both MCF-7/T47D cells from the placental villi (starting from 6 to 24 h) suggest that breast cancer cells migrated from the area of the placental explant. MMPs are known to be important facilitators of cell invasion through the matrigel; thus, we further analyzed MMP9/2 activity in media collected from placental MCF-7/T47D co-cultures and controls (Fig. 4e) . We found that 72 h after seeding, MMP2/9 activity in medium of MCF-7/T47D cells co-cultured with placental explants was significantly increased compared with separate cultures of MCF-7/T47D cells, placental explants or the sum of both (Fig. 4e , P , 0.05). These results further support the assumption that cell migration/invasion is a major cause of the disappearance of MCF-7/ T47D cells from the placental area.
Placental explant decreased the ERa level of breast cancer cells
Since our results suggest increased breast cancer cell motility near the placental explants, we analyzed the effect of first trimester human placental explants on MCF-7/T47D ERa levels. Decreased ERa expression was found in MCF-7/T47D cells co-cultured with placental explants compared with MCF-7/T47D cells cultured alone (Fig. 5a-e,  Fig. 5a and b, immunohistochemistry, 48 and 93% decreased ER expression in MCF-7 and T47D cells, respectively, ,0.05, Fig. 5d and e, western blotting, 65% decrease in MCF-7 cells, P , 0.05). Additional studies with MCF-7 cells demonstrated that reduced ER staining was observed all around the placental explants and not only in cells that were located near EVT releasing villi (data not shown).
The effect of first trimester placental soluble factors on MCF-7/T47D cells cultured on plastic substrate
The placenta could have affected the phenotype of breast cancer cells through direct cell to cell contact, by secreting soluble factors, or both. To evaluate the effect of placental soluble factors on MCF-7/T47D cells, they were exposed to media collected during placental explant culture [placental conditioned media (CM)]. As a control, MCF-7/ T47D cells were exposed to a medium that was previously layered for 24 h in inserts containing matrigel (Matrigel CM) or to fresh growth medium [Medium (control)]. Placental derived soluble factors prevented MCF-7/T47D cells from adhering to the plastic substrate (Fig. 6a, b , 40% inhibition, P , 0.05). Thus, many of the MCF-7/ T47D cells that were layered on the plastic substrate maintained a round morphology compared with the adherent control cells. Furthermore, placental soluble factors increased MCF-7 apoptotic events ( Fig. 6c) but had no effect on T47D cell apoptosis (data not shown).
The effect of MCF-7/T47D cells on placental explant proliferation and apoptosis
To investigate whether the effect of the placenta on breast cancer cells is specific to this organ and not a result of deficiency in the biological system, we analyzed the effect of breast cancer cells on placental explant proliferation and apoptosis rates. Co-culturing placenta with both T47D and MCF-7 cell lines did not change the proliferation and apoptosis rates of the trophoblast cells. Data are presented in Table II .
The area around the placental explant had fewer myeloma cells
Our data support the assumption that the placenta is a cancer-non-supportive microenvironment. Thus, we wished to test its effect on non-epithelial cells. We analyzed the effect of placental explants on CAG cell (myeloma cell line) distribution. We found that myeloma cells were absent from regions located near EVT releasing villi (Fig. 7a-c) . Further immunohistochemistry studies demonstrated that the area proximate to the EVT cells (positive for HLA-G but negative for CD138) was indeed empty of CAG cells (negative for HLA-G but positive for CD138); however, CAG cells were found near other placental areas that did not contain EVT cells.
Discussion
Breast cancer is often diagnosed at a more advanced stage in pregnant compared with matched non-pregnant women (Pereg et al., 2008) . However, the placenta and embryo are only rarely involved with metastatic disease and are described as a non-supportive microenvironment for cancer cells (Al-Adnani et al., 2007) . To study the unique effect of the placenta on breast cancer cells, we co-cultured human first trimester placental explants with MCF-7/T47D cells (breast cancer cell lines that express ERa). In this model, the placental explants are located above the matrigel, and EVT cells differentiate and migrate from the placental villi to the surrounding matrigel (Genbacev et al., 1992) . We showed that most of the breast cancer cells disappeared from areas proximate to the EVT cells, starting 6-24 h post-seeding. In contrast, more than 90% of the MCF-7/T47D cell that were cultured without the placenta (controls) formed aggregates and distributed equally in the wells, whereas the rest remained as single cells. Furthermore, apoptosis and reduced proliferation of breast cancer cells only partially contributed to their reduced numbers around the placental explants. Our findings suggest that breast cancer cells migrated/detached from the area of the EVT cells because (i) T47D cells changed their morphology to spindle-like cells that characterize motile cells (Tiezzi Representative photomicrographs of MMP2 activity (experiments with MCF-7) and MMP9 activity (experiments with T47D) in media collected from BCCLs cultured with/without placental explants for 72 h and of placental explants cultured alone. Furthermore, quantification of MMP2/9 activity in media collected from breast cancer cells or from placental explants cultured alone and together: experiments with MCF-7 (n ¼ 5) (4 h), experiments with T47D (n ¼ 4 -6) (4 h). Results were normalized to the total activity of breast cancer cells + placental explants. Statistically significant differences are indicated (*, P , 0.05).
The effect of human placenta on breast cancer cells et al., 2007) and MCF-7 cells rapidly formed elongated aggregates; (ii) This process was accompanied by elevated MMPs activity that is known to facilitate cell invasion through the matrigel; (iii) Placental soluble factors caused breast cancer cells to detach from plastic substrate; and (iv) breast cancer cells co-cultured with the placenta had reduced ERa expression.
Generally, ERa negative tumors are less differentiated, more aggressive, and have higher metastatic potential than ERa positive tumors (Putti et al., 2005; Bentzon et al., 2008) . In vitro studies showed that breast cancer cell motility is inhibited by ERa (Platet et al., 2004) .
Thus, the reduced ERa levels found in breast cancer cells following their co-culture with the placenta may have supported their migration. However, since breast cancer cells were eliminated, especially from areas located near EVT cells, whereas the reduced ERa expression of the breast cancer cells was found around all the placental explants, additional placental factors must have been involved in their elimination. Interestingly, decreased ERa was also found during normal pregnancies in the receptive uterus (Bazer et al., 2008) . Furthermore, decreased expression of ERa levels in breast cancer cells of pregnant women has been suggested previously (Shousha, 2000) . Our study is the first to show the influence of placental factors on the ERa expression of breast cancer cells.
We found that placental explants increased apoptosis of MCF-7 cells, especially in proximity to EVT cells. Interestingly, several lines of evidence suggest that through embryonic implantation, uterine epithelial cells undergo apoptosis at attachment sites (Galan et al., 2000) . The endometrial apoptosis occurred only beneath and around the embryonic attachment site compared with cells that were distant from the blastocyte (Galan et al., 2000) . Placental cells may synthesize a number of apoptotic triggering molecules, such as TNF-a, FasL, TRAIL (TNF-related apoptosis-inducing ligand) and INF and induce the death of neighboring cells (Aboagye-Mathiesen et al., 1996; Bowen et al., 2002; Fluhr et al., 2007; Bazer et al., 2009) . EVT cells produce elevated levels of INFs compared with other trophoblast cells in the presence of growth factors (GM-CSF + PDGF), (Aboagye-Mathiesen et al., 1994; AboagyeMathiesen et al., 1996; Sodek et al., 2008; Bazer et al., 2009) and INFg/b has tumor suppressor activities (Nicolini et al., 2006) .
We found that placental explants changed the morphology of T47D and MCF-7 cells. Instead of round MCF-7 colonies that were formed on matrigel, elongated aggregates were seen near the placental explants. Similar changes in MCF-7 aggregate elongation were demonstrated previously, as a result of the combined exposure of breast cancer cells to estrogen and progesterone (Sukocheva et al., 2009) . Noel et al. (1988) demonstrated that rapid MCF-7 cluster formation on the matrigel is a result of cell aggregation and not cell proliferation. Indeed, in order to rapidly form aggregates (6 h), the cells should have migrated on the matrigel. The MCF-7 cell cluster formed strand-like structures which soon moved away. MMPs are critical to the collective migration of tumor cells (Rorth et al., 2009) . Furthermore, past studies found that MT1-MMP (MMP2 activator) is a key enzyme in the proteolysis of collagen-rich ECM to generate space for migration and invasion of cell masses (Nabeshima et al., 2000; Wolf et al., 2007) . Indeed, we found elevated MMP2 activity, which supports migration of MCF-7 aggregates through the matrigel. T47D cells created very small aggregates and demonstrated a non-significant elevation of MMP2 activity levels in their medium. Instead, elevated MMP9 activity was found in T47D-placenta co-culture. MMP9, like MMP2, supports breast cancer cell invasion (Kunigal et al., 2007) and thus, their elevated levels together with the T47D morphological change to spindle-like cells and their rapid disappearance from the EVT area suggest that they migrated from this area. Both T47D and MCF-7 cells were eliminated from the placental area. However, few differences were observed between the placental effects on these two cell lines. The placenta had less of an effect on T47D cell death compared with MCF-7 cells. Furthermore, the placenta induced elevated MMP9 and had only a non-significant effect on MMP2 levels in T47D cells, whereas significantly elevated levels of MMP2, but not of MMP9, were observed in MCF-7 cells that were co-cultured with placenta. The reason for these differences may be attributed to the mutant p53 that is expressed by T47D cells (Lim et al., 2009) , while MCF-7 cells express wild-type p53. Mutant p53 have pro-survival effect which may protect cells from apoptosis (Lim et al., 2009) . Moreover, previous studies with sarcoma demonstrated that cells with mutant p53 overexpress MMP9, whereas wild-type 53 activate MMP2 promoter but inhibit MMP9 expression, both being observed in our system (Liu et al., 2006) . Malignant cells were eliminated mainly from the areas of EVT cell differentiation and implantation in the matrigel. Moreover, increased breast cancer cell apoptosis and decreased proliferation were also notable in the same areas, highlighting the unique effect of the EVT cells compared with the rest of the placental epithelial cells.
First trimester human placentas secrete a variety of factors. Many of these, including progesterone, IL-6, (epidermal growth factor) EGF, LIF and IGFII have been shown to modulate MMPs secretion and/or trophoblast invasion and implantation (Goldman et al., 2006; Cohen et al., 2007) . During implantation, placental factors activate signaling pathways that modulate the expression of genes that are important for attachment of the trophectoderm to the uterine wall, silence progesterone and ERa genes, induce apoptosis and promote other pregnancy-supporting functions (Galan et al., 2000; Bazer et al., 2008 Bazer et al., , 2009 ). In our biological system, placental explants modulated phenotypes of breast cancer cell lines in a similar way to its effect on the uterus during embryonic implantation (i.e. cell adhesion, ERa expression and apoptosis).
Breast cancer cells had no effect on proliferation and apoptosis of trophoblast cells, suggesting that the placental effect on neighboring cells is indeed specific for this organ and not a result of deficiency in the biological system, such as nutrient limitation.
In conclusion, our study demonstrates for the first time that embryonic organ/pregnancy conditions affect the phenotype of breast cancer cells. Furthermore, we propose that breast cancer cells migrated from the implantation site of the placenta (that contains EVT cells), suggesting it is a non-supporting microenvironment for breast cancer cells. Elimination of myeloma cells from the placental area supports previously published data, which suggested that the placental non-supporting effect on cancer cells is a general phenomenon. We hypothesize that factors and pathways involved in normal placental implantation also modified biological characteristics of the malignant cells in the placental area. The molecular pathways responsible for the altered breast cancer phenotype are now being explored. Identification of these pathways may enable the development of new therapeutic approaches.
